Literature DB >> 25257614

Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma.

Edward J Gettings1, Christopher T Hackett1, Thomas F Scott2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25257614     DOI： 10.1177/1352458514549403

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  36 in total

Review 1.  Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors.

Authors:  Dustin Anderson; Grayson Beecher; Nabeela Nathoo; Michael Smylie; Jennifer A McCombe; John Walker; Rajive Jassal
Journal:  Neurooncol Pract       Date:  2018-10-04

Review 2.  Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.

Authors:  Melinda Liu; Yuan Yu M Huang; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

3.  CNS inflammatory disorder after concurrent radiotherapy-temozolomide and nivolumab in a glioblastoma patient.

Authors:  Anna Luisa Di Stefano; Julien Savatovsky; Loic Feuvret; Chiara Villa; Vincent Reina; Micheline Pha; Caroline Houillier; Giulia Berzero; Ahmed Idbaih; Dimitri Psimaras
Journal:  Neuro Oncol       Date:  2019-01-01       Impact factor: 12.300

Review 4.  Cancer immunotherapy in patients with preexisting autoimmune disorders.

Authors:  Marco Donia; Magnus Pedersen; Inge Marie Svane
Journal:  Semin Immunopathol       Date:  2016-10-11       Impact factor: 9.623

Review 5.  Checkpoint Inhibitors.

Authors:  Lucie Heinzerling; Enrico N de Toni; Georg Schett; Gheorghe Hundorfean; Lisa Zimmer
Journal:  Dtsch Arztebl Int       Date:  2019-02-22       Impact factor: 5.594

6.  CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment.

Authors:  Yonghao Cao; Alyssa Nylander; Sriram Ramanan; Brittany A Goods; Gerald Ponath; Rana Zabad; Veronica L S Chiang; Alexander O Vortmeyer; David A Hafler; David Pitt
Journal:  Neurology       Date:  2016-03-16       Impact factor: 9.910

7.  PD-1 inhibition: a novel approach to the treatment of progressive multifocal leukoencephalopathy.

Authors:  Joseph R Berger
Journal:  Ann Transl Med       Date:  2019-12

Review 8.  Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition.

Authors:  Peter Chei-Way Pan; Aya Haggiagi
Journal:  Curr Oncol Rep       Date:  2019-11-27       Impact factor: 5.075

9.  SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019).

Authors:  M Majem; E García-Martínez; M Martinez; E Muñoz-Couselo; D Rodriguez-Abreu; R Alvarez; A Arance; A Berrocal; L de la Cruz-Merino; J A Lopez-Martin
Journal:  Clin Transl Oncol       Date:  2020-01-28       Impact factor: 3.405

Review 10.  Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management.

Authors:  Christophoros Astaras; Rita de Micheli; Bianca Moura; Thomas Hundsberger; Andreas F Hottinger
Journal:  Curr Neurol Neurosci Rep       Date:  2018-02-01       Impact factor: 5.081
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.